Berezin Alexander E
Private Hospital "Vita-Center", Zaporozhye, Ukraine; Internal Medicine Department, Medical University of Zaporozhye, Ukraine.
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S201-S208. doi: 10.1016/j.dsx.2016.12.032. Epub 2016 Dec 13.
Type 2 diabetes mellitus (T2DM) remains a leading cause of cardiovascular (CV) events and diseases worldwide. The aim of the review is to summarize our knowledge regarding clinical implementation of the biomarker-based strategy of the CV risk assessment in T2DM patient population. There is large body of evidence regarding use of the cardiac biomarkers to risk stratification at higher CV risk individuals who belongs to general population and cohort with established CV disease. Although T2DM patients have higher incidence of macrovascular and microvascular CV complications than the general population, whether cardiac biomarkers would be effective to risk stratification of the T2DM is not fully understood. The role of natriuretic peptides, galectin-3, interleukins, growth differentiation factor-15, as well as biomarkers of endothelial dysfunction are widely discussed. In conclusion, future directions, which associate with discovering of novel biomarkers and their best combinations to provide additional predictive information beyond other traditional CV risk factors, are discussed.
2型糖尿病（T2DM）仍然是全球心血管（CV）事件和疾病的主要原因。本综述的目的是总结我们关于T2DM患者群体中基于生物标志物的CV风险评估临床应用的知识。有大量证据表明，心脏生物标志物可用于一般人群和已确诊CV疾病队列中CV风险较高个体的风险分层。尽管T2DM患者发生大血管和微血管CV并发症的发生率高于一般人群，但心脏生物标志物对T2DM风险分层是否有效尚不完全清楚。利钠肽、半乳糖凝集素-3、白细胞介素、生长分化因子-15以及内皮功能障碍生物标志物的作用得到了广泛讨论。总之，本文讨论了未来的研究方向，即发现新的生物标志物及其最佳组合，以提供超越其他传统CV风险因素的额外预测信息。
